Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 9
1996 8
1997 8
1998 19
1999 24
2000 27
2001 14
2002 14
2003 14
2004 10
2005 14
2006 12
2007 12
2008 8
2009 13
2010 9
2011 6
2012 5
2013 8
2014 11
2015 8
2016 2
2017 6
2018 2
2020 3
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12916011

261 results

Results by year

Filters applied: . Clear all
Page 1
Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
Amin J, Moore A, Carr A, French MA, Law M, Emery S, Cooper DA; OzCombo 1 and 2 Investigators. Amin J, et al. HIV Clin Trials. 2003 Jul-Aug;4(4):252-61. doi: 10.1310/K2U9-QC2V-1Y3V-5DYF. HIV Clin Trials. 2003. PMID: 12916011 Clinical Trial.
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators. French M, et al. HIV Clin Trials. 2002 May-Jun;3(3):177-85. doi: 10.1310/9n21-1hg1-7n1q-jkw1. HIV Clin Trials. 2002. PMID: 12032876 Clinical Trial.
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group. Joly V, et al. Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13. doi: 10.1128/AAC.46.6.1906-1913.2002. Antimicrob Agents Chemother. 2002. PMID: 12019107 Free PMC article. Clinical Trial.
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M. Squires KE, et al. AIDS. 2000 Jul 28;14(11):1591-600. doi: 10.1097/00002030-200007280-00015. AIDS. 2000. PMID: 10983646 Clinical Trial.
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M. Eron JJ Jr, et al. AIDS. 2000 Jul 28;14(11):1601-10. doi: 10.1097/00002030-200007280-00016. AIDS. 2000. PMID: 10983647 Clinical Trial.
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG. Bussmann H, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102. J Acquir Immune Defic Syndr. 2009. PMID: 19282782 Free PMC article. Clinical Trial.
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team. Ungsedhapand C, et al. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701. doi: 10.1097/00126334-200406010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15167288 Clinical Trial.
261 results